CA2470970A1 - Post-conditioning for the reduction of ischemic-reperfusion injury in the heart and other organs - Google Patents
Post-conditioning for the reduction of ischemic-reperfusion injury in the heart and other organs Download PDFInfo
- Publication number
- CA2470970A1 CA2470970A1 CA002470970A CA2470970A CA2470970A1 CA 2470970 A1 CA2470970 A1 CA 2470970A1 CA 002470970 A CA002470970 A CA 002470970A CA 2470970 A CA2470970 A CA 2470970A CA 2470970 A1 CA2470970 A1 CA 2470970A1
- Authority
- CA
- Canada
- Prior art keywords
- tissue
- organ
- heart
- perfusion
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000000056 organ Anatomy 0.000 title claims abstract description 102
- 210000002216 heart Anatomy 0.000 title claims abstract description 59
- 230000010411 postconditioning Effects 0.000 title abstract description 26
- 206010063837 Reperfusion injury Diseases 0.000 title description 15
- 230000009467 reduction Effects 0.000 title description 8
- 230000010410 reperfusion Effects 0.000 claims abstract description 53
- 230000006378 damage Effects 0.000 claims abstract description 50
- 238000000034 method Methods 0.000 claims abstract description 50
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 41
- 208000014674 injury Diseases 0.000 claims abstract description 40
- 210000001519 tissue Anatomy 0.000 claims description 96
- 230000010412 perfusion Effects 0.000 claims description 68
- 230000000302 ischemic effect Effects 0.000 claims description 55
- 210000004351 coronary vessel Anatomy 0.000 claims description 30
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- 239000003223 protective agent Substances 0.000 claims description 11
- 210000004204 blood vessel Anatomy 0.000 claims description 10
- 230000002669 organ and tissue protective effect Effects 0.000 claims description 10
- 230000006835 compression Effects 0.000 claims description 6
- 238000007906 compression Methods 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 3
- 210000000936 intestine Anatomy 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 210000002027 skeletal muscle Anatomy 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 abstract description 25
- 208000010125 myocardial infarction Diseases 0.000 abstract description 17
- 230000017531 blood circulation Effects 0.000 description 31
- 210000004165 myocardium Anatomy 0.000 description 29
- 230000000694 effects Effects 0.000 description 11
- 230000010413 ischemic postconditioning Effects 0.000 description 11
- 206010061216 Infarction Diseases 0.000 description 10
- 210000001367 artery Anatomy 0.000 description 9
- 210000003038 endothelium Anatomy 0.000 description 9
- 230000007574 infarction Effects 0.000 description 9
- 210000000440 neutrophil Anatomy 0.000 description 9
- 239000012530 fluid Substances 0.000 description 7
- 230000002530 ischemic preconditioning effect Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 102000004420 Creatine Kinase Human genes 0.000 description 6
- 108010042126 Creatine kinase Proteins 0.000 description 6
- 102000003896 Myeloperoxidases Human genes 0.000 description 6
- 108090000235 Myeloperoxidases Proteins 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
- 230000036770 blood supply Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 208000037906 ischaemic injury Diseases 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 206010028851 Necrosis Diseases 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- 230000003750 conditioning effect Effects 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 3
- 208000005189 Embolism Diseases 0.000 description 3
- 206010020565 Hyperaemia Diseases 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010064966 Myocardial oedema Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 229960005305 adenosine Drugs 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008753 endothelial function Effects 0.000 description 3
- 210000005003 heart tissue Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 208000001778 Coronary Occlusion Diseases 0.000 description 2
- 206010011086 Coronary artery occlusion Diseases 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000008828 contractile function Effects 0.000 description 2
- 238000007887 coronary angioplasty Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 239000002874 hemostatic agent Substances 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000002464 muscle smooth vascular Anatomy 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 238000011422 pharmacological therapy Methods 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 206010048961 Localised oedema Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000031074 Reinjury Diseases 0.000 description 1
- 229940122055 Serine protease inhibitor Drugs 0.000 description 1
- 101710102218 Serine protease inhibitor Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- IWXNYAIICFKCTM-UHFFFAOYSA-N cariporide Chemical compound CC(C)C1=CC=C(C(=O)N=C(N)N)C=C1S(C)(=O)=O IWXNYAIICFKCTM-UHFFFAOYSA-N 0.000 description 1
- 229950008393 cariporide Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009091 contractile dysfunction Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical group [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 229960002460 nitroprusside Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000002883 vasorelaxation effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3613—Reperfusion, e.g. of the coronary vessels, e.g. retroperfusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34327501P | 2001-12-21 | 2001-12-21 | |
| US60/343,275 | 2001-12-21 | ||
| PCT/US2002/041354 WO2003059266A2 (en) | 2001-12-21 | 2002-12-20 | Post-conditioning for the reduction of ischemic-reperfusion injury in the heart and other organs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2470970A1 true CA2470970A1 (en) | 2003-07-24 |
Family
ID=23345416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002470970A Abandoned CA2470970A1 (en) | 2001-12-21 | 2002-12-20 | Post-conditioning for the reduction of ischemic-reperfusion injury in the heart and other organs |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20040255956A1 (enExample) |
| EP (1) | EP1471849A4 (enExample) |
| JP (2) | JP2005514168A (enExample) |
| AU (1) | AU2002364231A1 (enExample) |
| CA (1) | CA2470970A1 (enExample) |
| WO (1) | WO2003059266A2 (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2463415C (en) | 2001-10-25 | 2012-02-07 | Emory University | Catheter for modified perfusion |
| US20070160645A1 (en) * | 2001-10-25 | 2007-07-12 | Jakob Vinten-Johansen | PostConditioning System And Method For The Reduction Of Ischemic-Reperfusion Injury In The Heart And Other Organs |
| US7668594B2 (en) | 2005-08-19 | 2010-02-23 | Cardiac Pacemakers, Inc. | Method and apparatus for delivering chronic and post-ischemia cardiac therapies |
| US20060100639A1 (en) * | 2004-11-05 | 2006-05-11 | G&L Consulting, Llc | System and method for the treatment of reperfusion injury |
| EP1827298A4 (en) * | 2004-12-22 | 2011-09-28 | Univ Emory | THERAPEUTIC APPARATUS FOR IMPROVING THE PROTECTIVE EFFECTS OF POST-CONDITIONING ORGANS |
| US7837650B1 (en) | 2004-12-30 | 2010-11-23 | Advanced Cardiovascular Systems, Inc. | Method and apparatus to prevent reperfusion injury |
| US7295874B2 (en) * | 2005-01-06 | 2007-11-13 | Cardiac Pacemakers, Inc. | Intermittent stress augmentation pacing for cardioprotective effect |
| US7962208B2 (en) | 2005-04-25 | 2011-06-14 | Cardiac Pacemakers, Inc. | Method and apparatus for pacing during revascularization |
| US20060259088A1 (en) * | 2005-05-13 | 2006-11-16 | Pastore Joseph M | Method and apparatus for delivering pacing pulses using a coronary stent |
| US7894896B2 (en) | 2005-05-13 | 2011-02-22 | Cardiac Pacemakers, Inc. | Method and apparatus for initiating and delivering cardiac protection pacing |
| US7917210B2 (en) | 2005-05-13 | 2011-03-29 | Cardiac Pacemakers, Inc. | Method and apparatus for cardiac protection pacing |
| US7774057B2 (en) | 2005-09-06 | 2010-08-10 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression for cardiac protection |
| US8108034B2 (en) | 2005-11-28 | 2012-01-31 | Cardiac Pacemakers, Inc. | Systems and methods for valvular regurgitation detection |
| US7885710B2 (en) * | 2005-12-23 | 2011-02-08 | Cardiac Pacemakers, Inc. | Method and apparatus for tissue protection against ischemia using remote conditioning |
| US9533127B2 (en) | 2006-07-24 | 2017-01-03 | Abbott Cardiovascular Systems Inc. | Methods for inhibiting reperfusion injury |
| US7717855B2 (en) * | 2006-12-06 | 2010-05-18 | The Hospital For Sick Children | System for performing remote ischemic preconditioning |
| US8615296B2 (en) | 2007-03-06 | 2013-12-24 | Cardiac Pacemakers, Inc. | Method and apparatus for closed-loop intermittent cardiac stress augmentation pacing |
| US20090287069A1 (en) * | 2007-11-25 | 2009-11-19 | Ic Therapeutics | Methods and apparatus for repeated ischemic conditioning treatment of hypertension and other medical conditions |
| US20100105993A1 (en) * | 2007-05-23 | 2010-04-29 | Ic Therapeutics, Inc. | Methods and apparatus for noninvasive ischemic conditioning |
| WO2008148062A1 (en) * | 2007-05-23 | 2008-12-04 | Ic Therapeutics, Inc. | Apparatus and methods for controlled ischemic conditioning |
| US20100185220A1 (en) * | 2007-05-23 | 2010-07-22 | Ic Therapeutics, Inc. | Apparatus and methods for controlled ischemic conditioning |
| US8986342B2 (en) * | 2007-11-25 | 2015-03-24 | Ic Therapeutics | Methods and apparatus for repeated ischemic conditioning treatment of hypertension and other medical conditions |
| WO2009097118A1 (en) | 2008-01-29 | 2009-08-06 | Cardiac Pacemakers, Inc | Configurable intermittent pacing therapy |
| US8140155B2 (en) | 2008-03-11 | 2012-03-20 | Cardiac Pacemakers, Inc. | Intermittent pacing therapy delivery statistics |
| WO2009117086A2 (en) | 2008-03-17 | 2009-09-24 | Cardiac Pacemakers, Inc. | Deactivation of intermittent pacing therapy |
| US8244352B2 (en) * | 2008-06-19 | 2012-08-14 | Cardiac Pacemakers, Inc. | Pacing catheter releasing conductive liquid |
| US8639357B2 (en) | 2008-06-19 | 2014-01-28 | Cardiac Pacemakers, Inc. | Pacing catheter with stent electrode |
| US9037235B2 (en) | 2008-06-19 | 2015-05-19 | Cardiac Pacemakers, Inc. | Pacing catheter with expandable distal end |
| US9409012B2 (en) | 2008-06-19 | 2016-08-09 | Cardiac Pacemakers, Inc. | Pacemaker integrated with vascular intervention catheter |
| US8457738B2 (en) | 2008-06-19 | 2013-06-04 | Cardiac Pacemakers, Inc. | Pacing catheter for access to multiple vessels |
| WO2010002456A1 (en) * | 2008-07-01 | 2010-01-07 | Cardiac Pacemakers, Inc. | Pacing system controller integrated into indeflator |
| AU2010248156B2 (en) * | 2009-05-13 | 2015-01-22 | CellAegis Devices Inc. | Performance enhancement |
| US8983600B2 (en) | 2009-05-15 | 2015-03-17 | Cardiac Pacemakers, Inc. | Method and apparatus for safety control during cardiac pacing mode transition |
| US8958873B2 (en) | 2009-05-28 | 2015-02-17 | Cardiac Pacemakers, Inc. | Method and apparatus for safe and efficient delivery of cardiac stress augmentation pacing |
| EP2448474B1 (en) * | 2009-06-23 | 2019-09-18 | Boris Leschinsky | Devices for remote ischemic preconditioning and near-continuous blood pressure monitoring |
| US8812104B2 (en) | 2009-09-23 | 2014-08-19 | Cardiac Pacemakers, Inc. | Method and apparatus for automated control of pacing post-conditioning |
| JP5503012B2 (ja) | 2009-10-30 | 2014-05-28 | カーディアック ペースメイカーズ， インコーポレイテッド | 迷走神経サージと反応とを用いるペースメーカ |
| US20110190807A1 (en) * | 2010-02-01 | 2011-08-04 | The Hospital For Sick Children | Remote ischemic conditioning for treatment and prevention of restenosis |
| US20110190727A1 (en) * | 2010-02-02 | 2011-08-04 | Boston Scientific Scimed, Inc. | Intervascular catheter, system and method |
| US8911469B2 (en) * | 2010-03-25 | 2014-12-16 | Neocardium, Limited | Methods and apparatus for optimal remote ischemic preconditioning (ORIP) for preventing ischemia-reperfusion injuries to organs |
| WO2011121402A2 (en) * | 2010-03-31 | 2011-10-06 | The Hospital For Sick Children | Use of remote ischemic conditioning to improve outcome after myocardial infarction |
| SG10201502029RA (en) * | 2010-04-08 | 2015-05-28 | Hospital For Sick Children | Use of remote ischemic conditioning for traumatic injury |
| US9155869B2 (en) | 2010-04-30 | 2015-10-13 | Abbott Cardiovascular Systems Inc. | Catheter having inflation and deflation lumen useful for preventing or reducing reperfusion injury |
| US8540669B2 (en) | 2010-04-30 | 2013-09-24 | Abbott Cardiovascular Systems Inc. | Catheter system providing step reduction for postconditioning |
| US9168361B2 (en) | 2010-04-30 | 2015-10-27 | Abbott Cardiovascular Systems Inc. | Balloon catheter exhibiting rapid inflation and deflation |
| WO2011137372A1 (en) | 2010-04-30 | 2011-11-03 | Abbott Cardiovascular Systems Inc. | Improved balloon catheter exhibiting rapid inflation and deflation |
| US8708996B2 (en) | 2010-04-30 | 2014-04-29 | Abbott Cardiovascular Systems, Inc. | Methods and device for synergistic mitigation of reperfusion injury after an ischemic event |
| US8480650B2 (en) | 2010-04-30 | 2013-07-09 | Abbott Cardiovascular Systems Inc. | Method for increased uptake of beneficial agent and ejection fraction by postconditioning procedures |
| US9533124B2 (en) | 2011-04-14 | 2017-01-03 | Abbott Cardiovascular Systems Inc. | Reperfusion injury devices |
| US8764789B2 (en) | 2011-04-15 | 2014-07-01 | CellAegis Devices Inc. | System for performing remote ischemic conditioning |
| WO2013077283A1 (ja) * | 2011-11-21 | 2013-05-30 | 国立大学法人大阪大学 | 腎動脈アブレーション用のカテーテルおよびシステム |
| WO2013082458A1 (en) | 2011-12-02 | 2013-06-06 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
| USD708338S1 (en) | 2012-08-15 | 2014-07-01 | CellAegis Devices Inc. | Cuff for remote ischemic conditioning |
| US10252052B2 (en) | 2013-03-15 | 2019-04-09 | The Hospital For Sick Children | Methods relating to the use of remote ischemic conditioning |
| AU2013203746B2 (en) | 2013-03-15 | 2015-05-07 | Cellaegis Devices, Inc. | Gas Powered System for Performing Remote Ischemic Conditioning |
| WO2014140832A2 (en) | 2013-03-15 | 2014-09-18 | The Hospital For Sick Children | Treatment of erectile dysfunction using remote ischemic conditioning |
| US10272241B2 (en) | 2013-03-15 | 2019-04-30 | The Hospital For Sick Children | Methods for modulating autophagy using remote ischemic conditioning |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4962095A (en) * | 1989-02-15 | 1990-10-09 | E. R. Squibb & Sons, Inc. | Method of reducing pre-and post-ischemic myocardial arrhythmias and fibrillation |
| US4931464A (en) * | 1989-02-15 | 1990-06-05 | E. R. Squibb & Sons, Inc. | Method of reducing pre- and post-ischemic myocardial arrhythmias and fibrillation |
| US5181518A (en) * | 1991-02-04 | 1993-01-26 | Mcdonagh Paul F | Method of evaluating cardioprotective agents |
| US5195942A (en) * | 1991-08-12 | 1993-03-23 | Institute Of Critical Care Medicine | Cardiac arrest treatment |
| US5695457A (en) * | 1994-07-28 | 1997-12-09 | Heartport, Inc. | Cardioplegia catheter system |
| US5730698A (en) * | 1995-05-09 | 1998-03-24 | Fischell; Robert E. | Balloon expandable temporary radioisotope stent system |
| US6295990B1 (en) * | 1998-02-03 | 2001-10-02 | Salient Interventional Systems, Inc. | Methods and systems for treating ischemia |
| CA2463415C (en) * | 2001-10-25 | 2012-02-07 | Emory University | Catheter for modified perfusion |
-
2002
- 2002-12-20 JP JP2003559431A patent/JP2005514168A/ja not_active Withdrawn
- 2002-12-20 US US10/499,052 patent/US20040255956A1/en not_active Abandoned
- 2002-12-20 WO PCT/US2002/041354 patent/WO2003059266A2/en not_active Ceased
- 2002-12-20 EP EP02799307A patent/EP1471849A4/en not_active Ceased
- 2002-12-20 AU AU2002364231A patent/AU2002364231A1/en not_active Abandoned
- 2002-12-20 CA CA002470970A patent/CA2470970A1/en not_active Abandoned
-
2009
- 2009-03-23 JP JP2009070979A patent/JP2009172394A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1471849A4 (en) | 2011-01-05 |
| AU2002364231A1 (en) | 2003-07-30 |
| WO2003059266A3 (en) | 2004-03-25 |
| US20040255956A1 (en) | 2004-12-23 |
| AU2002364231A8 (en) | 2003-07-30 |
| JP2009172394A (ja) | 2009-08-06 |
| WO2003059266A2 (en) | 2003-07-24 |
| JP2005514168A (ja) | 2005-05-19 |
| EP1471849A2 (en) | 2004-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20040255956A1 (en) | Post-conditioning for the reduction of ischemic-reperfusion injury in the heart and other organs | |
| JP4514838B2 (ja) | 過増殖性の血管疾患を予防するための医薬組成物 | |
| Murphy et al. | Surgical revascularization following unsuccessful percutaneous transluminal coronary angioplasty | |
| US5108365A (en) | Transluminal infusion of magnesium during coronary angioplasty | |
| Gore et al. | Preliminary experience with synchronized coronary sinus retroperfusion in humans. | |
| JPH09504274A (ja) | 人工表面および血管面の血栓を予防する酸化窒素付加物の利用 | |
| US20060205671A1 (en) | Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury | |
| Yamazaki et al. | Synchronized coronary venous tetroperfusion: prompt improvement of left ventricular function in experimental myocardial ischemia | |
| Kelly et al. | Effect of 100% oxygen administration on infarct size and left ventricular function in a canine model of myocardial infarction and reperfusion | |
| JP2005500330A (ja) | ステント配置を伴う動脈血管形成術後のステント内血栓症および合併症を予防するためのマグネシウムの使用 | |
| Scheidt et al. | Mechanical ciculatory assistance with the intraaortic balloon pump and other counterpulsation devices | |
| US5523292A (en) | Method of preventing restenosis following coronary angioplasty | |
| Geary et al. | Quantitative assessment of infarct size reduction by coronary venous retroperfusion in baboons | |
| LeVeen et al. | Venous and arterial occlusive disease treated by enzymatic clot lysis | |
| Maksan et al. | Reduction of hepatic reperfusion injury by antithrombin III and aprotinin | |
| RU2365380C1 (ru) | Способ лечения острого инфаркта миокарда | |
| Sirin et al. | Aprotinin reduces injury of the spinal cord in transient ischemia | |
| Acar et al. | Studies of controlled reperfusion after ischemia: XVII. Reperfusion conditions: Controlled reperfusion through an internal mammary artery graft—A new technique emphasizing fixed pressure versus fixed flow | |
| Zughaib et al. | Beneficial effects of MDL 74,405, a cardioselective water soluble α tocopherol analogue, on the recovery of function of stunned myocardium in intact dogs | |
| Schumacher et al. | Streptokinase thrombolysis in experimental coronary artery thrombosis: pattern of reflow and effect of a stenosis | |
| US20240050470A1 (en) | Method for Inhibiting Reperfusion Injury | |
| Sevitt | Diagnosis and Management of Massive Pulmonary Embolism [Abridged] Thromboembolism and its Prevention | |
| Norman et al. | Heparin reduces the intimal hyperplasia seen in microvascular vein grafts | |
| Cliffton | Bronchial artery perfusion for treatment of advanced lung cancer | |
| Groban et al. | Cloricromene reduces infarct size and alters postischaemic blood flow defects in dog myocardium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |